Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $747.10 | 8 | 62.1% |
| Education | $255.97 | 3 | 21.3% |
| Consulting Fee | $200.00 | 1 | 16.6% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $597.07 | 7 | $0 (2024) |
| United Therapeutics Corporation | $377.58 | 3 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $228.42 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $259.79 | 3 | Actelion Pharmaceuticals US, Inc. ($141.59) |
| 2023 | $578.49 | 5 | Actelion Pharmaceuticals US, Inc. ($378.49) |
| 2022 | $228.43 | 3 | United Therapeutics Corporation ($123.02) |
| 2021 | $136.36 | 1 | United Therapeutics Corporation ($136.36) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2024 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $52.60 | General |
| 09/18/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $118.20 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 06/07/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $88.99 | General |
| Category: Cardiology | ||||||
| 10/25/2023 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Cardio-pulmonary | ||||||
| 06/29/2023 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $89.99 | General |
| Category: Cardiology | ||||||
| 04/18/2023 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $78.40 | General |
| Category: Cardiology | ||||||
| 04/11/2023 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $105.14 | General |
| Category: Cardiology | ||||||
| 03/22/2023 | Actelion Pharmaceuticals US, Inc. | — | Food and Beverage | In-kind items and services | $104.96 | General |
| 08/18/2022 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Education | In-kind items and services | $76.99 | General |
| Category: Cardiology | ||||||
| 06/11/2022 | Bayer HealthCare Pharmaceuticals Inc. | Adempas (Drug) | Food and Beverage | In-kind items and services | $28.42 | General |
| Category: Hematology | ||||||
| 06/10/2022 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $123.02 | General |
| Category: PAH | ||||||
| 04/27/2021 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $136.36 | General |
| Category: PAH | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 168 | 224 | $63,586 | $16,888 |
| 2022 | 4 | 191 | 240 | $70,071 | $19,384 |
| 2021 | 4 | 127 | 169 | $48,199 | $14,045 |
| 2020 | 3 | 80 | 93 | $31,157 | $7,802 |
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 70 | 97 | $30,715 | $8,409 | 27.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 54 | 73 | $17,052 | $4,541 | 26.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 30 | 30 | $13,201 | $3,441 | 26.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 14 | 24 | $2,617 | $496.25 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 76 | 111 | $33,454 | $10,002 | 29.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 47 | 47 | $20,237 | $5,167 | 25.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 49 | 62 | $13,762 | $3,814 | 27.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 19 | 20 | $2,617 | $401.49 | 15.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 46 | 72 | $21,067 | $6,623 | 31.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 41 | 41 | $17,654 | $4,959 | 28.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 31 | $6,727 | $1,926 | 28.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2021 | 16 | 25 | $2,751 | $536.00 | 19.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 39 | 39 | $16,793 | $4,263 | 25.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 24 | 35 | $10,241 | $2,551 | 24.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 17 | 19 | $4,123 | $988.09 | 24.0% |
About Dana Klanderud, ARNP
Dana Klanderud, ARNP is a Family healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/02/2017. The National Provider Identifier (NPI) number assigned to this provider is 1194246959.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dana Klanderud, ARNP has received a total of $1,203 in payments from pharmaceutical and medical device companies, with $259.79 received in 2024. These payments were reported across 12 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($747.10).
As a Medicare-enrolled provider, Klanderud has provided services to 566 Medicare beneficiaries, totaling 726 services with total Medicare billing of $58,119. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Practice Information
- Specialty Family
- Location Seattle, WA
- Active Since 07/02/2017
- Last Updated 11/03/2021
- Taxonomy Code 363LF0000X
- Entity Type Individual
- NPI Number 1194246959
Products in Payments
- TYVASO (Drug) $377.58
- OPSUMIT (Drug) $255.97
- Adempas (Drug) $228.42
- UPTRAVI (Drug) $183.54
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Doctors in Seattle
Dr. Kevan Petterson, Dnp, Fnp, DNP, FNP
Family — Payments: $55,987
Dr. Kaitlin Brasier, D.n.p., A.r.n.p., Rn, D.N.P., A.R.N.P., RN
Family — Payments: $27,842
Ms. Karen Johnson, Arnp, ARNP
Family — Payments: $14,117
Omeid Heidari, Phd, Msn, Anp-C, PHD, MSN, ANP-C
Family — Payments: $12,629
Lilly Silva, Rn, Fnp, Msn, RN, FNP, MSN
Family — Payments: $9,101
Amy Perez, Fnp, FNP
Family — Payments: $8,589